4,901 trials
Nonalcoholic Steatohepatitis (NASH) · Primary Sclerosing Cholangitis (PSC)
Primary: Pharmacokinetic (PK) Parameter: AUClast of Cilofexor — 5381.0; 2972.6; 8223.7; 2756.7 h*ng/mL
Healthy
Primary: Baseline Corrected Maximum Observed Plasma Concentration (Cmax[Adj]) of Levothyroxine Sodium — 67.258; 60.552 Nanogram per milliliter (ng/mL)
Clexane is Administered to Healthy Volunteers
Primary: Anti-FXa Cmax — 0.999; 0.926 IU/mL
Pain
Primary: Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade - — 0.3635; 0.7358; 0.0887; -0.1983 Degrees Centigrade
Human Immunodeficiency Virus · AIDS Virus
Primary: Change From Baseline in Plasma HIV-1 RNA — -1.39; -1.66; -0.95 log10 copies/mL
Alzheimer Disease · Mild Cognitive Impairment
Primary: Flortaucipir PET Imaging (Quantitative) — 1.31; 1.13; 1.15; 1.08 standardized uptake value ratio (SUVr) — p=<0.0001
Advanced Cancer · Metastatic Cancer
Primary: Number of Participants With One or More Drug Related Adverse Events — 12; 13 Participants
Frontotemporal Dementia
Primary: Qualitative Evaluation of Flortaucipir PET Scans — 0; 0; 13 Participants
Cystic Fibrosis
Primary: Intra-subject Change From Baseline of CFTR-mediated Total Chloride Transport as Measured by Nasal Potential Difference (NPD). — 1.86; -0.75; -1.11; 1.66 mV
Composite Lymphoma · Grade 3b Follicular Lymphoma · Stage I Diffuse Large B-Cell Lymphoma
Primary: Number of Participants With a Grade 3 or Higher Toxicity Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 13…
Age-Related Macular Degeneration
Primary: Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) — 0.810; 0.526; 2.762; 1.833 letters
Smoking Cessation
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation — 5; 2; 1; 4 participants
Bacterial Vaginosis
Primary: Safety of LACTIN-V in Healthy Pre-menopausal Women. — 0; 0; 0; 0 participants
Healthy
Primary: Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose — 416.48; 417.77 milliseconds (msec)
Uveal Melanoma · Choroid Neoplasm
Primary: Occurrence of Adverse Events — 1; 3; 5; 0 Participants